Parkinson's Disease
A Brief Description of Parkinson's Disease
Parkinson's disease (PD) is a progressive neuromuscular disorder that occurs in middle-age to older adults. The disorder has a mean beginning of about 55 years of age. The incidence of Parkinson's disorder increases with age. PD affects about 0.15% percent of the population (American Psychiatric Association [APA], 2000). PD was first described in 1817 by James Parkinson's "Essay on the Shaking Palsy."
In 95% of PD cases diagnoses there is no genetic association (no one in the family has it) and these cases are designated as sporadic PD. In the small number of remaining cases the disorder is inherited (Dauer & Przedborski, 2003). A condition known as secondary Parkinsonism that resembles the physical presentation of PD can be brought on by a number of drugs or other conditions such as dopamine antagonist medications, hypoxia, and from brain tumors (APA, 2000).
The Cause of PD
The etiology (cause) of PD is not known but there are distinct neuropathological signs of PD that have been relatively well described. The neural loops that connect the basal ganglia and the thalamus in midbrain are composed of both inhibitory and excitatory pathways. These pathways combine together to form two basic routes: a direct route that induces physical actions (composed of excitatory neural loops) and an indirect neural route that decreases or inhibits actions (composed of inhibitory neural loops). PD results from involvement in both of these areas. The two major neuropathological characteristics of PD are (Goetz, Emre & Dubois, 2009):
1. A massive loss of the nirgrostriatal dopaminergic neurons. The loss of dopaminergic neurons means that a deficiency of the brain neurotransmitter dopamine is the characteristic feature of PD (Goetz, Emre & Dubois, 2009). The nirgrostriatal tract is one of the major projections in the brain that is involved in movement. However, the principal pathology of PD appears to affect the dopamine-producing neurons in an area of the brain known as the substantia nigra pars compacta. The neurotransmitter dopamine is produced by neurons in the substantia nigra from DOPA (which is a precursor of melanin) and then is transported along the axons...
What is worth noting here is the fact that behavior disturbances, ranging in severity from repeated questioning to physical violence, are common (National Institute of Mental Health, 1989). It is unclear whether Alzheimer's disease represents a single entity or several variants. Some experts believe that there are distinct subtypes of Alzheimer's disease, such as Lewy body disease (in which the signs of Parkinson's disease, visual hallucinations or alterations in alertness
Although the severities of congestive signs may be similar, medical evaluation should be instructed to determine whether there is accompanying proof of cardiovascular disease. Physical proof of cardiovascular disease contains the narrow pulse pressure, cool arms, and legs, and sometimes changed mentation, with supporting proof sometimes provided by reducing serum sodium level and deteriorating renal function. Cardiovascular disease is frequently difficult to recognize through phone contact but may be
) between 20 and 50. Studies have shown that people with multiple sclerosis who exercise: c.) have less fatigue How many people in the United States are diagnosed with multiple sclerosis every week? A b.) about 200 ("Take the FDA Consumer") Dealing with Depression As depression is reportedly the most common psychiatric disorder in multiple sclerosis (MS) patients, those caring for MS patients who express any sort of suicidal ideation should be closely monitored and referred
Phase II consists of efficacy trials of the drug, which are tested on volunteers of the target population. When everything goes right, the drug manufacturer discusses the development process, continued human testing, other concerns and protocols for phase III with the FDA. Phase III is the more extensive. It is at this time that the manufacture can work for the accelerated development and review of the drug. Treatment IND
Schizophrenia In "Yoga Therapy for Schizophrenia," Bangalore & Varambally (2012) explore a gap in the research on treatments for schizophrenia. The authors point out that pharmacological interventions and traditional psychotherapeutic techniques have remained "sub-optimal," if not totally ineffective (p. 85). A lack of meaningful progress in schizophrenia research gives rise to more nuanced and cross-disciplinary understandings of how the disease can be treated. The authors note that prior research has revealed
It focuses on the controversy, and provides answers to the question of whether or not stem cell research is providing the benefits in the ways in which the public believes they will soon be benefiting from the research. The authors contend that partisan responses to the public's concerns over stem cell research are delaying the benefits of much needed treatments and cures that can be derived from stem cell research
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now